Chronic Sildenafil for Severe Diaphragmatic Hernia
NCT00133679 is a phase 4 interventional trial sponsored by University of California, San Francisco. As of 18 Nov 2026, it was terminated. It studies Placebo and Sildenafil in Hernia, Diaphragmatic, Hypertension, Pulmonary and 1 more condition. The registry lists an enrollment of 9 participants at 3 sites in 1 country. The registry lists a start date of 28 Feb 2006 and a primary completion date of 31 Jul 2013.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT00133679 |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional trial |
| Lead sponsor | University of California, San Francisco |
| Enrollment | 9 |
| Registered sites | 3 |
| Countries | 1 |
| Conditions | Hernia, Diaphragmatic, Hypertension, Pulmonary and Hypoplasia, Pulmonary |
| Drugs | Placebo and Sildenafil |
| Start | 28 Feb 2006 |
| Primary completion | 31 Jul 2013 |
| Study completion | 31 Oct 2013 |
| Last update posted | 13 Jan 2021 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Roberta L Keller, MD
University of California, San Francisco
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Children's Hospital of Los Angeles
Los Angeles
- University of California San Francisco Children's Hospital
San Francisco
- Children's Memorial Hospital
Chicago
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT00133679
Each answer restates registry values shown on this page.
What is NCT00133679?
NCT00133679 is a phase 4 interventional trial sponsored by University of California, San Francisco. It studies Placebo and Sildenafil in Hernia, Diaphragmatic, Hypertension, Pulmonary and 1 more condition.
Who leads NCT00133679?
The registry names Roberta L Keller, MD (principal investigator, University of California, San Francisco) as the overall official.
Where does NCT00133679 run?
The registry lists 3 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT00133679 study?
The registered drug and biological interventions are Placebo and Sildenafil.
When did NCT00133679 end?
The registry lists a primary completion date of 31 Jul 2013 and a study completion date of 31 Oct 2013. The sponsor last updated the record on 13 Jan 2021.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.